A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma
Completed
Boehringer Ingelheim
Phase 2
2011-03-01
This study will compare efficacy and safety of different regimens of olodaterol
administration in asthma (once daily, twice daily) with placebo in a complete cross-over
design each within one of the two daily dose groups (medium or high daily dose).
The aim of the study is to establish the olodaterol dose in the ethanolic fixed dose
combination (FDC) with BI 54903 which is equivalent in bronchodilator effect and systemic
exposure to the 5 µg olodaterol reference dose in the aqueous inhalation solution (AIS).
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
